The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Tuberculosis is the world’s deadliest infectious disease and kills 1.4 million people a year. The latest diagnostic tests can rapidly and accurately diagnose TB. New medicines can help prevent and cure TB. Yet two years after a United ...
After a decade of strong commitments to fight the twin epidemics of HIV and tuberculosis (TB), a decline in international funding and the rapid shifting of the financial burden to affected countries is in danger of reversing lifesaving ...
The Tajik Ministry of Health and Médecins Sans Frontières (MSF) began a comprehensive paediatric tuberculosis (TB) care programme in 2011. The paediatric TB project in Dushanbe aims to decrease the TB morbidity and mortality rates ...
Out of Step 2017 includes the results of a 29-country survey on national TB policies and practices. The report was created to identify gaps in implementation and monitor progress towards ending TB.
The MSF Access Campaign’s Out of Step report series reports on gaps in implementation of WHO guidelines and policies that are proven to reduce TB incidence and death and to monitor progress towards ending TB.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key ...
This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market ...
This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market ...